RxDoctor Payments DataLook up a doctor →

Teri Smith, APRN

Acute Care · Hot Springs National Park, ARNPI 1497735120

Payments from drug & device makers

$13,866in general payments, 2019–2025

Across 705 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • MDD US Operations, LLC$1K
  • Biogen$991
  • Novartis$839
  • Pfizer$804
  • SK Life Science, Inc.$774
  • plus $7K from 36 others

What the payments were for

  • Speaking & faculty fees$320%
  • Food & beverage$13,827100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,866 in reported general payments places this provider in the 95th percentile of 321 acute care providers in Arkansas.

See all acute care providers in Arkansas

Medicare billing

Part B allowed, 2024
$100,388
Medicare patients
519
Services billed
2,962

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab13$615,356
AubagioTeriflunomide25$230,140
Nurtec OdtRimegepant Sulfate117$170,784
Avonex (4 Pack)Interferon Beta-1a19$155,327
Emgality PenGalcanezumab-Gnlm120$141,374
PanzygaImmun Glob G(Igg)-Ifas/Glycine14$139,021
Aimovig AutoinjectorErenumab-Aooe106$135,179
QuliptaAtogepant64$75,327
UbrelvyUbrogepant57$73,140
Glatiramer Acetate23$42,000
AptiomEslicarbazepine Acetate21$37,470
BotoxOnabotulinumtoxina23$30,190
BriviactBrivaracetam16$26,094
RytaryCarbidopa/Levodopa13$21,892
Ajovy AutoinjectorFremanezumab-Vfrm19$19,475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$472$615,35613 claims
PfizerNurtec Odt, Panzyga$804$309,805131 claims
SanofiAubagio$190$230,14025 claims
AbbVieQulipta, Ubrelvy, Botox$1,959$178,657144 claims
BiogenAvonex (4 Pack)$991$155,32719 claims
Sunovion Pharmaceuticals Inc.Aptiom$194$37,47021 claims
UCB, Inc.Briviact$678$26,09416 claims
Amneal Pharmaceuticals LLCRytary$737$21,89213 claims
SK Life Science, Inc.Xcopri$774$16,48212 claims
Lilly USA, LLCReyvow$528$11,79316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 321 acute care providers in Arkansas.

Other acute care in Hot Springs National Park

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →